Liberalizing Hospital Proximity Requirements for Children/Young Adults with Low Burden B-ALL Receiving Tisagenlecleucel. Read more about Liberalizing Hospital Proximity Requirements for Children/Young Adults with Low Burden B-ALL Receiving Tisagenlecleucel.
An AI Model Classifies Risks of Early Relapse Post-CAR T Cell Therapy in a Multi-Center Real-World Population with DLBCL. Read more about An AI Model Classifies Risks of Early Relapse Post-CAR T Cell Therapy in a Multi-Center Real-World Population with DLBCL.
Efficacy and Safety of Belumosudil as Compared with Best Available Therapy for the Treatment of cGVHD in the US. Read more about Efficacy and Safety of Belumosudil as Compared with Best Available Therapy for the Treatment of cGVHD in the US.
Role of race and ethnicity in survival among children/young adults with relapsed ALL: a Children's Oncology Group report. Read more about Role of race and ethnicity in survival among children/young adults with relapsed ALL: a Children's Oncology Group report.
Single cell proteomics characterization of bone marrow hematopoiesis with distinct Ras pathway lesions. Read more about Single cell proteomics characterization of bone marrow hematopoiesis with distinct Ras pathway lesions.
Real-World Outcomes of Infections Following Tisagenlecleucel in Patients with B-Cell ALL: A CIBMTR Analysis. Read more about Real-World Outcomes of Infections Following Tisagenlecleucel in Patients with B-Cell ALL: A CIBMTR Analysis.
Characterization and prediction of hematotoxicity in pediatric patients receiving tisagenlecuecel. Read more about Characterization and prediction of hematotoxicity in pediatric patients receiving tisagenlecuecel.
Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapy. Read more about Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapy.
Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma. Read more about Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma.
Outcomes of Brexucabtagene Autoleucel in Relapsed/Refractory Acute Lymphoblastic Leukemia Patients with CNS Involvement. Read more about Outcomes of Brexucabtagene Autoleucel in Relapsed/Refractory Acute Lymphoblastic Leukemia Patients with CNS Involvement.
